ABT (Abbott) יתרת חוב כוללת של החברה

The decline in profits from pandemic testing was offset by demand for medical devices, which was reflected in the dynamics of the total debt load, where the indicator value reaches 30.20. Abbott Laboratories (ABT) maintains stable income through the scalability of its glucose sensors. Meanwhile, a portion of assembly and logistics has been outsourced to third-party contractors. This approach optimizes expenses and reduces the risks associated with dependence on in-house capacities.

Abbott Laboratories (ABT) maintains a dominant position in the healthcare sector through broad asset diversification. This metric aggregates the total volume of borrowed funds, reflecting the overall credit burden on capital. By analyzing the current debt status, the investor assesses the balance between debt service costs and expansion rates. An optimal leverage level ensures the development of innovative medical devices without the risk of default. A steady reduction in liabilities confirms the financial stability of the company's ecosystem.